TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22338128

Group type: EXPERIMENTAL
Intervention: Ultrasonic surface positioning group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Anatomic landmark group
Number of subjects: 150
Study: 19478257

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (250 mg, twice daily) added to metronidazole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 50
Study: 17725894

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 0
Study: 15573850

Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 doses of 6 mg IV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11300573

Group type: EXPERIMENTAL
Intervention: Schematic threatening faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schematic friendly faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schematic neutral faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schematic angry faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schematic sad or scheming faces
Number of subjects: 0
Study: 9129063

Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 RNA level >100,000 copies/mL
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Baseline CD4 cell percent <15%
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Increased HIV-1 RNA levels after baseline
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: CD4 cell percent dropped to <15%
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Log10 increase in HIV-1 RNA copy numbers
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: 5 percentage point decrement in CD4 cell percent
Number of subjects: 254
Study: 7880700

Group type: EXPERIMENTAL
Intervention: Mivacurium pretreatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suxamethonium alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 100
Study: 2646536

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control (No Milrinone)
Number of subjects: 230
Study: 33454

Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole in 54 patients
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (50 patients)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 31893603

Group type: EXPERIMENTAL
Intervention: LMA-proseal (LMAP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LMA-classic (LMAC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LMA-flexible (LMAF)
Number of subjects: 90
Study: 28521773

Group type: EXPERIMENTAL
Intervention: Red yeast rice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 60
Study: 25264190

Group type: EXPERIMENTAL
Intervention: Family Constellation Seminars (FCSs) - 3-day intervention
Number of subjects: 104
Study: 26231850

Group type: EXPERIMENTAL
Intervention: Standard treatment with focus on lifestyle (n = 90)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 10-session, 1.5 h/week group treatment with focus on parenting (n = 45)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Same group treatment as 2) with additional follow-up sessions (n = 45)
Number of subjects: 180
Study: 23601801

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FA) implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 0
Study: 21088650

Group type: EXPERIMENTAL
Intervention: Belatacept (more intensive regimen)
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Belatacept (less intensive regimen)
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 1425
Study: 17945409

Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 16600931

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) diet
Number of subjects: 39
Study: 14710100

Group type: EXPERIMENTAL
Intervention: 40 mg vaginally administered isosorbide mononitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11268494

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide (1000 mg/m2 day 1), epidoxorubicin (60 mg/m2 day 1), and vincristine (1.4 mg/m2 day 1) every 14 days for six cycles followed by cisplatin (40 mg/m2 days 1 & 2) and etoposide (100 mg/m2 days 1‐3) every 14 days for four cycles, with prophylactic filgrastim (300 mcg subcutaneously from day 5 to day 10)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, epidoxorubicin, and vincristine followed by cisplatin and etoposide
Number of subjects: 16
Study: 9048699

Group type: EXPERIMENTAL
Intervention: Vignette with 'isumaluttuq' label
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Vignette with 'demon possession' label
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Vignette with 'mental illness' label
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Vignette behavior (threatening or withdrawn)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Female gender, more education, less familiarity with behavior, perception of less likelihood of recovery
Number of subjects: 137
Study: 7698963

Group type: EXPERIMENTAL
Intervention: Improved technique for pleural drain insertion
Number of subjects: 0
Study: 3235816

Group type: EXPERIMENTAL
Intervention: 10 mg DZ MM i.v. + placebo i.m.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg DZ i.v. + placebo i.m.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg DZ MM i.m. + placebo i.v.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg DZ i.m. + placebo i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo i.v. + placebo i.m.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All active substances (DZ MM i.v., DZ i.v., DZ MM i.m., DZ i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DZ MM i.m.
Number of subjects: 0
Study: 31278414

Group type: EXPERIMENTAL
Intervention: Biocon‐700
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound
Number of subjects: 50
Study: 28648567

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 27
Study: 26586042

Group type: EXPERIMENTAL
Intervention: Male players
Number of subjects: 66

Group type: COMPARATOR
Intervention: Players with a history of ankle sprain
Number of subjects: 66

Group type: COMPARATOR
Intervention: Players without a history of ankle sprain
Number of subjects: 66
Study: 24716668

Group type: EXPERIMENTAL
Intervention: 200 μg selenium-enriched yeast (SelenoPrecise®) daily for 12 months
Number of subjects: 472

Group type: COMPARATOR
Intervention: Matching placebo tablets daily for 12 months
Number of subjects: 472
Study: 23692173

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy
Number of subjects: 464

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 464
Study: 20617412

Group type: COMPARATOR
Intervention: MitraClip device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 18398972

Group type: EXPERIMENTAL
Intervention: Higher breast milk viral load at 1 week, 1 month, and 4 months
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Elevated breast milk sodium concentration (> or =13 mmol/L) at 4 months
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Elevated sodium concentration at 1 week postpartum
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Consistent viral shedding and high breast milk viral load
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sodium concentrations later in breast-feeding
Number of subjects: 138
Study: 16618589

Group type: EXPERIMENTAL
Intervention: Individualised and structured nursing intervention with education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no nursing intervention)
Number of subjects: 0
Study: 14666354

Group type: EXPERIMENTAL
Intervention: Triancinolone 10 mg/ml intralesional injection
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline solution 0.9% injection (placebo)
Number of subjects: 14
Study: 10995093

Group type: EXPERIMENTAL
Intervention: Village-based surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Health centre-based surgery
Number of subjects: 56
Study: 7943838

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.75% (6-8 ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous bupivacaine (1.2 mg.min-1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural saline (6-8 ml)
Number of subjects: 20
Study: 3036980

Group type: EXPERIMENTAL
Intervention: Topical drops containing combinations of antibiotics and steroids (including one with an anti-fungal agent)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Boric acid in spirit
Number of subjects: 27
Study: 31044759

Group type: EXPERIMENTAL
Intervention: High-salt diet (15.2 g/day) after a low-salt diet (2.9 g/day) for 7 days each
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: High-salt diet (15.2 g/day)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Consumption of extra salt
Number of subjects: 374
Study: 27634780

Group type: EXPERIMENTAL
Intervention: Kin Keeper(SM) cancer prevention intervention delivered by community health workers (CHWs) via existing community programs
Number of subjects: 0
Study: 24261345

Group type: EXPERIMENTAL
Intervention: Nicardipine-sevoflurane (Group N)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Remifentanil-sevoflurane (Group R)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-sevoflurane (Group D)
Number of subjects: 62
Study: 22486470

Group type: EXPERIMENTAL
Intervention: Bilateral Balanced Occlusion (BBO)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Canine Guidance (CG)
Number of subjects: 44
Study: 20796315

Group type: EXPERIMENTAL
Intervention: Arabinogalactan extract (ResistAid™)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 18097227

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 300/75 mg/m twice daily plus two nucleoside reverse transcriptase inhibitors
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 300/75 mg/m twice daily
Number of subjects: 21
Study: 16882678

Group type: EXPERIMENTAL
Intervention: Oral CoQ(10) (100 mg tid)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) (60% of peak VO(2), five times a week)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo plus ET
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CoQ(10) plus ET
Number of subjects: 23
Study: 14714358

Group type: EXPERIMENTAL
Intervention: Jiangya Capsule (JYC)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nimodipine (Control)
Number of subjects: 35
Study: 10813709

Group type: EXPERIMENTAL
Intervention: Combined therapy consisting of intraarterial cisplatin infusion (2 mg/kg every 8 weeks) and systemic interferon-alpha (3 million IU/m2 subcutaneously 3 times a week)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intraarterial cisplatin infusion (2 mg/kg every 8 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intraarterial cisplatin infusion
Number of subjects: 68
Study: 8782256

Group type: EXPERIMENTAL
Intervention: Combination of neomycin, polymyxin B, and dexamethasone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 108
Study: 1738550

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: General conditioning exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vestibular suppressant medication
Number of subjects: 0
Study: 6675729

Group type: EXPERIMENTAL
Intervention: Experimenter presence
Number of subjects: 53

Group type: COMPARATOR
Intervention: Experimenter absence
Number of subjects: 53
Study: 31787595

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30572991

Group type: COMPARATOR
Intervention: Non-intervention (insulin treatment only)
Number of subjects: 46
Study: 26305613

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 63
Study: 24271142

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg daily
Number of subjects: 71
Study: 22714138

Group type: EXPERIMENTAL
Intervention: ECG feedback (N = 21)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group with video recording (N = 25)
Number of subjects: 46
Study: 21073054

Group type: EXPERIMENTAL
Intervention: DEC (300 mg) + Doxycycline (200 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: DEC (300 mg) + Placebo
Number of subjects: 44
Study: 17917553

Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 2227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2227
Study: 16330719

Group type: EXPERIMENTAL
Intervention: IMPACT intervention (n = 906)
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual primary care (n = 895)
Number of subjects: 1801

Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Number of subjects: 1801
Study: 11895065

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogs (bimatoprost, latanoprost, travoprost)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unoprostone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogs
Number of subjects: 0
Study: 10646748

Group type: EXPERIMENTAL
Intervention: Spectacle correction for early-onset refractive accommodative esotropia
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (typical onset after 2 years old)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Prematurity as a risk factor
Number of subjects: 43
Study: 7667331

Group type: EXPERIMENTAL
Intervention: Cold environment at 5 degrees C (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-HT1A agonist ipsapirone (IPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLAC) at 28 degrees C
Number of subjects: 0
Study: 2497632

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fermented-then-pasteurized milk (FPM)
Number of subjects: 16
Study: 658012

Group type: EXPERIMENTAL
Intervention: Metapramine (19560 R.P.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clorimipramine
Number of subjects: 0
Study: 30945802

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Traditional pathway
Number of subjects: 247
Study: 28002105

Group type: EXPERIMENTAL
Intervention: Cryosurgery with more-aggressive freezing techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryosurgery with less-aggressive freezing techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryosurgery on the scalp
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical treatment with ingenol mebutate gel, 0.015% after 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical treatment with vehicle gel after 3 weeks
Number of subjects: 0
Study: 26186553

Group type: EXPERIMENTAL
Intervention: Documentation of patient-physician care planning discussions within one month of metastatic diagnosis
Number of subjects: 665

Group type: COMPARATOR
Intervention: No documentation of patient-physician care planning discussions
Number of subjects: 665
Study: 23391319

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 32
Study: 21181475

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (100 mg/m², 1-hour infusion, weekly for 6 weeks)
Number of subjects: 74
Study: 19097797

Group type: EXPERIMENTAL
Intervention: Laterally wedged orthoses
Number of subjects: 66

Group type: COMPARATOR
Intervention: Neutral orthotic group (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (Laterally wedged orthoses and Neutral orthotic)
Number of subjects: 66
Study: 16990723

Group type: EXPERIMENTAL
Intervention: PPOS
Number of subjects: 53
Study: 15149512

Group type: EXPERIMENTAL
Intervention: Vitamin B12 cream applied twice daily for 8 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 8 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vitamin B12 cream
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 49
Study: 10828706

Group type: EXPERIMENTAL
Intervention: Sweeping of the membranes
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Uterine stimulation with oxytocin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 9048527

Group type: EXPERIMENTAL
Intervention: Codfish
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mackerel
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Herring
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Plaice
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Histamine release test
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Specific IgE tests
Number of subjects: 38

Group type: COMPARATOR
Intervention: Maxisorp RAST
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Inhibition of the codfish Maxisorp RAST
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cross-reactivity to shrimp or milk
Number of subjects: 38
Study: 8392210

Group type: EXPERIMENTAL
Intervention: Isoprenaline (beta 1, beta 2, and beta 3-agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol 20 mg (beta 1/beta 2 antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol 5 mg (beta 1/beta 2 antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg (beta 1 antagonist)
Number of subjects: 0
Study: 2881423

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (d‐Tc) 50 micrograms/kg + alfentanil (Alf) 20 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (d‐Tc) 50 micrograms/kg + alfentanil (Alf) 50 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alf 10 micrograms/kg + Alf 20 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alf 10 micrograms/kg + Alf 50 micrograms/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lower-dose alfentanil groups
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 29878062

Group type: EXPERIMENTAL
Intervention: WEB + SN
Number of subjects: 5290

Group type: EXPERIMENTAL
Intervention: WEB + NRT
Number of subjects: 5290

Group type: EXPERIMENTAL
Intervention: WEB + SN + NRT
Number of subjects: 5290

Group type: EXPERIMENTAL
Intervention: WEB
Number of subjects: 5290
Study: 26787203

Group type: EXPERIMENTAL
Intervention: DVD promoting breast cancer awareness
Number of subjects: 2

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 2
Study: 24296871

Group type: EXPERIMENTAL
Intervention: Allopurinol (200 mg/day) for 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 70
Study: 22751025

Group type: EXPERIMENTAL
Intervention: Yoga of Awareness intervention (8-week duration)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Yoga practice rates
Number of subjects: 39
Study: 20483519

Group type: EXPERIMENTAL
Intervention: 2.5min DVD without practice
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: 4.5min DVD with manikin practice
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: 9min DVD with manikin practice and scenario training
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Scenario training
Number of subjects: 396

Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 396
Study: 18613385

Group type: EXPERIMENTAL
Intervention: Haemopressin (1 mg tri‐glycyl‐lysin‐vasopressin acetate, 2mg i.v. immediately followed by 1 mg i.v. q4h for 5 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Glypressin (2mg i.v. immediately followed by 1 mg i.v. q4h for 5 days)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Haemopressin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Glypressin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Haemopressin and Glypressin
Number of subjects: 41
Study: 16636120

Group type: EXPERIMENTAL
Intervention: Once-weekly (OW) alendronate 70 mg
Number of subjects: 833

Group type: COMPARATOR
Intervention: Once-weekly (OW) risedronate 35 mg
Number of subjects: 833
Study: 14645423

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 127
Study: 11080325

Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation and relapse prevention intervention
Number of subjects: 140
Study: 8827792

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Doxapram (0.5 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1426825

Group type: EXPERIMENTAL
Intervention: Acamprosate (666 mg, 2 tablets)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 4059470

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29168022

Group type: EXPERIMENTAL
Intervention: Blastocyst stage transfer
Number of subjects: 388

Group type: COMPARATOR
Intervention: Cleavage stage transfer
Number of subjects: 388
Study: 27806364

Group type: EXPERIMENTAL
Intervention: Erythritol
Number of subjects: 485

Group type: COMPARATOR
Intervention: Sorbitol (Control)
Number of subjects: 485
Study: 24162380

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Simvastatin (GS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Gemcitabine plus Placebo (GP)
Number of subjects: 114
Study: 22628588

Group type: EXPERIMENTAL
Intervention: Large-diameter metal-on-metal total hip replacement (MoM THR)
Number of subjects: 119